Overview

A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1b/2 study to investigate the efficacy and safety of LBL-007 plus Tislelizumab when administered in combination with bevacizumab plus capecitabine to participants with colorectal cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

BeiGene

Treatments:

Bevacizumab
Capecitabine